$2 Billion is the total value of Novo Holdings A/S's 18 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 22.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTI | VANGUARD INDEX FDStotal stk mkt | $606,366,000 | +4.4% | 5,958,200 | 0.0% | 30.36% | -16.2% | |
| OPHT | OPHTHOTECH CORP | $584,187,000 | +18.6% | 13,807,308 | 0.0% | 29.24% | -4.9% | |
| VGK | VANGUARD INTL EQUITY INDEX Fftse europe etf | $251,910,000 | +0.9% | 4,202,000 | 0.0% | 12.61% | -19.1% | |
| INGN | INOGEN INC | $244,526,000 | +36.6% | 10,838,898 | 0.0% | 12.24% | +9.6% | |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $128,496,000 | – | 6,402,366 | +100.0% | 6.43% | – |
| AKBA | New | AKEBIA THERAPEUTICS INC | $84,280,000 | – | 3,032,774 | +100.0% | 4.22% | – |
| FLXN | FLEXION THERAPEUTICS INC | $48,074,000 | -18.1% | 3,566,262 | 0.0% | 2.41% | -34.3% | |
| T107PS | WRIGHT MED GROUP INC | $18,393,000 | +1.1% | 585,759 | 0.0% | 0.92% | -18.9% | |
| TETRAPHASE PHARMACEUTICALS INC | $12,141,000 | +23.9% | 900,000 | 0.0% | 0.61% | -0.7% | ||
| TTPH | TETRAPHASE PHARMACEUTICALS INC | $12,141,000 | +23.9% | 900,000 | 0.0% | 0.61% | -0.7% | |
| WMGIZ | WRIGHT MED GROUP INCright 03/01/2019 | $7,033,000 | +79.5% | 4,720,065 | 0.0% | 0.35% | +43.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-14 |
| SC 13G/A | 2024-05-14 |
| 144 | 2024-05-10 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.